TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01048892
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04021017
Drug: Estradiol Hemihydrate Transdermal System
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants who have had their first period or have a bone age greater than or equal to 14 years will receive PrClimara® 25 (estradiol hemihydrate transdermal system - 25 mcg/day) as a weekly patch, for 24 months. Participants who have not yet had their first period and have a bone age below 14 years will receive an increasing dose of estrogen. These participants will be initiated on graduated dose of transdermal 17-β estradiol patches: 3.1 mcg/day (1/8 patch) for first six-months, 6.2 mcg/day (1/4 patch) for second six-months, 12.5 mcg/day (1/2 patch) for third six-months and 25 mcg/day (full patch) for final six-months.
Study: NCT01098500
Drug: Tyrosine kinase inhibitors
Normalized name: BCR-ABL tyrosine kinase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lapatinib, erlotinib, gefitinib, dasatinib, imatinib, nilotinib (analyzed as a class of drugs, not by individual drug)
Study: NCT03452488
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral capsules
Study: NCT02044848
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01127880
Drug: Ancef or Clindamycin
Normalized name: clindamycin Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 gm of Ancef or 300 mg Clindamycin for those who are penicillin allergic
Study: NCT01127880
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: .9% Normal Saline as a placebo
Study: NCT03523312
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral capecitabine at 825 mg/m2 BID on the days of RT. 5 Fluorouracil (5FU) at 250mg/m2/day, 7 days per week by a continuous IV infusion via an outpatient infusion pump) may be used instead at the discretion of the treating physician.
Study: NCT02198495
Drug: Supplementation of ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02068157
Drug: Photodynamic Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undergo image-guided I-PDT
Study: NCT02198495
Drug: Supplementation of iron sucrose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04079413
Drug: GP40071
Approvals — FDA: no, EMA: no, PMDA: no
Description: GP40071, 100 per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake.
Study: NCT04079413
Drug: NovoRapid® Penfill®
Approvals — FDA: no, EMA: no, PMDA: no
Description: NovoRapid® Penfill®, 100 per milliliters (U/mL) (dose range of 1 unit to 80 units) self-administered by SC injection, immediately (within 5-10 minutes) before meal intake.
Study: NCT03805984
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered ID on Day 0 and Week 4.
Study: NCT01216956
Drug: Extended-release nicotinic acid versus placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voluntary men with mixed dyslipidemia and abdominal obesity will receive extended release nicotinic acid. The dose of niaspan will be up-titrated for 3 weeks starting at 500 mg/d in order to reach 2g/d at start of week 4 dose which will be continued until the end of week 8. After a wash-out period of 3 weeks, they will receive placebo for 8 weeks. According to their randomization arm, subjects will receive either in first place placebo followed by extended release nicotinic acid or the opposite.
Study: NCT00514943
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: experimental drug taken once daily orally
Study: NCT02196688
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is a capsule in the form of 1mg and 5mg, orally, once daily, 3 weeks on/ 1 week off
Study: NCT02062359
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: On days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml dextrose 5% in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
Study: NCT00002599
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00002599
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00644501
Drug: DiaPep277
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0mg dose, injected subcutaneously at baseline and every 3 months thereafter (at 0, 3, 6, 9, 12, 15, 18, 21 months)for a total of 8 administrations.
Study: NCT00444808
Drug: Intranasal calcitonin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00063089
Drug: S. aureus Immune Globulin Intravenous (Human) 5%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00314548
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: nebulize for 30 mins
Study: NCT01583166
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 1:200,000 epinephrine
Study: NCT03106259
Drug: FURESTEM-RA Inj.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-interventional observational study
Study: NCT00239512
Drug: Indomethacin and Ibuprofen
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01219764
Drug: Rabeprazole, metronidazole, Clarithromycin, Amoxicillin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose arm:Rabeprazole (20mg), metronidazole (500mg), Clarithromycin (500mg) and Amoxicillin (1000mg) twice daily for a period of 7 days.~Half dose arm: Rabeprazole (10mg), metronidazole (250mg), Clarithromycin (250mg) and Amoxicillin (500mg) twice daily for a period of 7 days.
Study: NCT01514838
Drug: ASP1941
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral
Study: NCT01514838
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral, used only during placebo run-in period
Study: NCT04028349
Drug: Ad26.ZEBOV/MVA-BN-Filo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candidate Ebola Vaccine
Study: NCT00964834
Drug: Doxycycline and Valortim
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Days 1-5 100mg IV Doxycycline BID over 60 minutes. Day 6 20mg/kg Valortim IV over 60 minutes.
Study: NCT00964834
Drug: Placebo Antibiotic and Valortim
Normalized name: beclometasone and antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Days 1-5 20mg/kg IV Normal Saline BID over 60 minutes. Day 6 20mg/kg IV Valortim over 60 minutes.
Study: NCT01212822
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT01212822
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT00022230
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00022230
Drug: doxorubicin hydrochloride
Normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT03976687
Drug: EYP001a
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablets
Study: NCT01172496
Drug: treprostinil diethanolamine
Normalized name: treprostinil 1 MG (as treprostinil diethanolamine) 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be administered a 1 mg dose of treprostinil diethanolamine as a single tablet, and treprostinil diethanolamine oral solution 0.25 mg dose every 2 hours for four doses (1 mg total).
Study: NCT00005962
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01571999
Drug: Inhaled GSK573719
Approvals — FDA: no, EMA: no, PMDA: no
Description: All subjects will receive a single dose of GSK573719 (125mcg) in treatment period 1
Study: NCT01103310
Drug: BAY94-9392
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04074421
Drug: Probiotic Formula
Normalized name: Probiotic Formula
Approvals — FDA: no, EMA: no, PMDA: no
Description: A probiotic called Enterococcus faecium, 500mg, triple one day for 4 weeks.
Study: NCT04074421
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo oral tablet that has no therapeutic effect
Study: NCT01353274
Drug: Micamlo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan plus Amlodipine T40/A5
Study: NCT03994705
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Pre-conditioning therapy
Study: NCT01871493
Drug: LY2605541
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered subcutaneous (SQ)
Study: NCT03761030
Drug: Placebo Oral Tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25/100 placebo tablets
Study: NCT04445857
Drug: Calcitonin presented as Miacalcic® ampoules 100 IU/ml (1ml) intravenously
Approvals — FDA: no, EMA: no, PMDA: no
Description: coadministration of calcitonin intravenously and a single-shot hyperbaric bupivacaine
Study: NCT01858116
Drug: [68Ga]ABY-025
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous injection followed by PET imaging
Study: NCT01144039
Drug: HG-group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01144039
Drug: Placebo-group
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01844401
Drug: ProAir® HFA
Approvals — FDA: no, EMA: no, PMDA: no
Description: ProAir® HFA 180 mcg (administered as 2 actuations of 90 mcg of albuterol base/actuation ex-mouthpiece) orally inhaled, single dose
Study: NCT03164564
Drug: Oral TDF/FTC
Approvals — FDA: no, EMA: no, PMDA: no
Description: TDF/FTC 300 mg/200 mg fixed dose combination tablet
Study: NCT03164564
Drug: Placebo for oral CAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets
Study: NCT03164564
Drug: Placebo for oral TDF/FTC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets
Study: NCT03164564
Drug: Placebo for CAB LA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered as one 3 mL intramuscular injection in the gluteal muscle
Study: NCT00644176
Drug: azithromycin immediate release (Zithromax)
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: azithromycin IR 500 mg tablet by mouth for 1 dose
Study: NCT00644176
Drug: azithromycin SR
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2.0 g by mouth in the form of liquid for 1 dose
Study: NCT03557931
Drug: ASP4345
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT03557931
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT02560870
Drug: Active Comparator:Aloe Vera mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: mouthwash( Aloe Vera),10 ml by patients routinely washed two times in one day for about 30 seconds for two weeks.
Study: NCT03372330
Drug: Standard care for sepsis and PAD
Approvals — FDA: no, EMA: no, PMDA: no
Description: The standard medications care for the patient with PAD included antiplatelet agents.
Study: NCT01656330
Drug: Profilnine SD
Normalized name: Profilnine SD (obsolete)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus dose of Profilnine SD 50 IU/kg administered by intravenous (IV) injection on Day 5. Interpretation by CTRL: Concentration type = Exact; Number = 50; unit=IU/kg; route: intraveous use.
Study: NCT01656330
Drug: Beriplex P/N
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single bolus dose of Beriplex P/N 50 IU/kg administered by intravenous (IV) injection on Day 5 Interpretation by CTRL: Concentration type = Exact ; Number = 50; unit=IU/kg; route : intravenous use
Study: NCT04029701
Drug: Ruyizhenbao Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruyizhenbao Pills are provided by Jinhe Tibetan Pharmaceutical Co., Ltd. Chinese national medicine permission number:Z63020289、Z63020064. Medication method: oral 4 pills once, twice a day, 4 weeks in a row.
Study: NCT03292406
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non active ingredients of CD11301
Study: NCT03292406
Drug: CD11301 0.03%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Gel
Study: NCT01676740
Drug: Iron Supplement,
Normalized name: Iron Supplement, 250 mg oral capsule, extended release
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pills to be swallowed
Study: NCT01676740
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of active drug or placebo
Study: NCT03292406
Drug: CD11301 0.06%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical Gel
Study: NCT04029701
Drug: Placebo of Ruyizhenbao Pill
Normalized name: placebo Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is provided by Jinhe Tibetan Pharmaceutical Co., Ltd.，which is made of malt dextrin as a matrix, similar shape and same color to the Ruyizhenbao Pill. Medication method: oral 4 pills once, twice a day, 4 weeks in a row.
Study: NCT00532350
Drug: QAT370
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00532350
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00142779
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01058018
Drug: RVX000222
Approvals — FDA: no, EMA: no, PMDA: no
Description: RVX000222 twice a day for 12 weeks
Study: NCT01058018
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo twice a day for 12 weeks
Study: NCT03048344
Drug: ORH-2014
Approvals — FDA: no, EMA: no, PMDA: no
Description: ORH-2014 capsule 5 mg orally with dose escalations of 5 mg intervals.
Study: NCT04393298
Drug: trifluridine/tipiracil
Normalized name: TRIFLURIDINE/TIPIRACIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will receive predefined doses of trifluridine/tipiracil (TFD/TPI) administered as film-coated tablets at pre-specified time points.
Study: NCT04393298
Drug: mFOLFOX6
Approvals — FDA: no, EMA: no, PMDA: no
Description: Study participants will receive predefined doses of oxaliplatin, Leucovorin and 5-fluorouracil as part of the mFOLFOX6 chemotherapy regimen administered as intravenous (iv) infusion at prespecified time points.
Study: NCT00309530
Drug: 5-fluorouracil, levamisol, interferon
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02691182
Drug: SPN-810
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00220532
Drug: Folic acid with riboflavin
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00239746
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200mg taken orally daily for 6-12 weeks
Study: NCT00239746
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg matched placebo taken orally daily for 6-12 weeks
Study: NCT04558190
Drug: Intralipid, 20% Intravenous Emulsion
Normalized name: Intralipid, 20% intravenous emulsion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid infusion
Study: NCT00595504
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two week supply of placebo tablets first dispensed at baseline. New two week supply of placebo dispensed at each biweekly visit for 8 consecutive weeks.
Study: NCT01183208
Drug: Intervention B
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 30 mg will consist of 3 sprays of the 10 mg strength spray applied topically to cervix (1 spray) and vaginal fornices (2 sprays)
Study: NCT01183208
Drug: Intervention C
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 150 mg will consist of 15 sprays of the 10 mg strength spray applied topically to cervix (5 sprays) and vaginal fornices (10 sprays)
Study: NCT00615264
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mannitol (excipient) 40 mg, administered as subcutaneous injection on 1, 3, 6, 9, 12, 15, 18 and 21 months.
Study: NCT04492358
Drug: standard of care
Approvals — FDA: no, EMA: no, PMDA: no
Description: The standard treatment used in each site will be administered to the patients assigned to the control group.
Study: NCT01583686
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Days -7 and -6: Cyclophosphamide 60 mg/kg/day X 2 days intravenous (IV) in 250 ml 5% dextrose in water (D5W) with Mesna 15 mg/kg/day X 2 days over 1 hr.
Study: NCT01538472
Drug: Y Zevalin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Starting dose: 0.4 mCi/kg by vein after Rituxan infusion on Day -14.
Study: NCT01538472
Drug: In Zevalin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imaging dose: 5 mCi by vein following Rituxan infusion on Day -21.
Study: NCT00243542
Drug: ACZONE Gel, 5%
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00243542
Drug: Vehicle
Normalized name: Drug vehicle
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04324346
Drug: FEC100 + Taxotere (EC90 + Taxotere) 3+3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Type of Chemotherapy
Study: NCT00964990
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Form=solution for injection, route=Subcutaneous injection. One injection of matching placebo every 28 days for up to 52 wks
Study: NCT00369538
Drug: hydrochlorothiazide, losartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: One administration of hydrochlorothiazide, 25 mg per day during 2 months, followed by a wash-out during 1 month, and then, two administrations of losartan per day,up to 100mg per day, during 2 months
Study: NCT02829723
Drug: BLZ945
Approvals — FDA: no, EMA: no, PMDA: no
Description: BLZ945 administered orally as a capsule. Up to five alternative dosing schedules were evaluated: once per day (QD) 7 days on/7 days off (i.e., administer BLZ945 for 7 days and suspend for 7 days), QD 4 days on/10 days off, twice per day (BID) 4 days on/10 days off, once weekly (Q1W) QD and Q1W BID.~Each cycle consisted of 28 days.
Study: NCT02829723
Drug: PDR001
Approvals — FDA: no, EMA: no, PMDA: no
Description: PDR001 400 mg administered via intravenous (i.v.) infusion every 4 weeks (Q4W)
Study: NCT01361425
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo 500mg 8/8h, orally
Study: NCT01701414
Drug: Placebo: 3cc of 0.9% Normal Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1cm lateral to the ultrasound probe, a 27 gauge needle and syringe will be used to inject 3cc of 0.9% NS subcutaneously. The SC group will then be cared for by the Emergency Department physicians according to their regular clinical practice
Study: NCT03340961
Drug: DFD-29 Extended Release Capsules (40 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Treatment
Study: NCT03340961
Drug: DFD-29 Extended Release Capsules (20 mg)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Treatment
Study: NCT03340961
Drug: Oraycea® (doxycycline) Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Treatment
Study: NCT03340961
Drug: Placebo Capsules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Treatment
Study: NCT01010295
Drug: doxycycline (tetracycline)
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: doxycycline 100 mg twice daily for 3 weeks
Study: NCT02856113
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alogliptin placebo-matching tablets.
Study: NCT01116609
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: unilateral leg infusion of Epinephrine 0.4 micrograms/m2/min
Study: NCT00114179
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given orally
Study: NCT04890535
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matching placebo oral suspension for TBAJ-587
Study: NCT02827201
Drug: FOLFIRI.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: For each cycle : 1 week out of 2 - injection at Day1, J15 Irinotécan 90 mg/m² at day1 in perfusion over 60 min in Y of folinic acid Folinic Acid 400 mg/m² (or 200 mg/m² Elvorine) at Day 1 in perfusion over 2 hours 5FU continu 2000 mg/m² during 46 hours Irinotécan at 90 mg/m² in perfusion over 60 mn at Day 3 (when 5FU perfusion is over)
Study: NCT00620854
Drug: Nasal Spray
Normalized name: Nasal Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 IU recombinant salmon calcitonin, single intranasal spray
Study: NCT03137784
Drug: NVA237 (glycopyrronium bromide)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In each treatment arm, patient will receive NVA237 (glycopyrronium bromide) 25 ug and 50 ug dose
Study: NCT01700075
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipidlowering: Atorvastatin (Liprimar) - 40mg per day. Antihypertensive: Diroton (Lisinopril, Gedeon Richter Ltd) - 10mg twice per day and Ditiazem (calcium bloker from the benthodiazepines, Lannacher, Austria) - 90mg per day.~Antihyperglycemic drugs: biguanides Metformin - 0.5 g two or tree times per day, or Exenatide - 5-10 µg per day.~Anti-inflammatory: TromboACC (acetylsalicylate acid) up to 2 g per day and/or Clopidogrel (thienopyridine class antiplatelet agent) - 75mg per day.
Study: NCT02132845
Drug: targeted therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Receive target-directed therapy
Study: NCT00415792
Drug: Arvekap, Pregnyl
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03067688
Drug: Temisartan+Amlodipine+Rosuvastatin (Combination drug)
Normalized name: amlodipine / telmisartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily(QD), 8weeks
Study: NCT03067688
Drug: Temisartan+Rosuvastatin
Normalized name: rosuvastatin and telmisartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: PO, Once daily(QD), 8weeks
Study: NCT00154778
Drug: Taxol, UFT,Leucovorin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03432793
Drug: Caffeine
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: oral solution, single dose
Study: NCT02076893
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Both study arms will receive as needed (PRN) ibuprofen to take home.
Study: NCT02076893
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple syrup suspension
Study: NCT03342261
Drug: DAA treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients were treated with direct-acting antiviral (DAA) treatment for 12 or 24 weeks